EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome

John Cha, Gregory Filatov, Steven J Smith, Arnold R Gammaitoni iD, Amélie Lothe iD, Thadd Reeder

Epilepsia Open · 2024

DOI: 10.1002/epi4.12873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von John Cha und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Fenfluramine, Epilepsies, Myoclonic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zogenix, Inc., now a part of UCB, UCB, Zogenix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In patients with Dravet syndrome (DS), fenfluramine reduced convulsive seizure frequency and provided clinical benefit in nonseizure endpoints (e.g., executive function, survival). In zebrafish mutant scn1 DS models, chronic fenfluramine treatment preserved neuronal cytoarchitecture prior to seizure onset and prevented gliosis; here, we extend these findings to a mammalian model of DS ( Scn1a +/− mice) by evaluating the effects of fenfluramine on neuroinflammation (degenerated myelin, activated microglia) and survival.

Methods

Scn1a +/− DS mice were treated subcutaneously once daily with fenfluramine (15 mg/kg) or vehicle from postnatal day (PND) 7 until 35‐37. Sagittal brain sections were processed for immunohistochemistry using antibodies to degraded myelin basic protein (D‐MBP) for degenerated myelin, or CD11b for activated (inflammatory) microglia; sections were scored semi‐quantitatively. Apoptotic nuclei were quantified by TUNEL assay. Statistical significance was evaluated by 1‐way ANOVA with post‐hoc Dunnett's test (D‐MBP, CD11b, and TUNEL) or Logrank Mantel‐Cox (survival).

Results

Quantitation of D‐MBP immunostaining per 0.1 mm 2 unit area of the parietal cortex and hippocampus CA3 yielded significantly higher spheroidal and punctate myelin debris counts in vehicle‐treated DS mice than in wild‐type mice. Fenfluramine treatment in DS mice significantly reduced these counts. Activated CD11b + microglia were more abundant in DS mouse corpus callosum and hippocampus than in wild‐type controls. Fenfluramine treatment of DS mice resulted in significantly fewer activated CD11b + microglia than vehicle‐treated DS mice in these brain regions. TUNEL staining in corpus callosum was increased in DS mice relative to wild‐type controls. Fenfluramine treatment in DS mice lowered TUNEL staining relative to vehicle‐treated DS mice. By PND 35‐37, 55% of control DS mice had died, compared with 24% of DS mice receiving fenfluramine treatment ( P = 0.0291). Significance This is the first report of anti‐neuroinflammation and pro‐survival after fenfluramine treatment in a mammalian DS model. These results corroborate prior data in humans and animal models and suggest important pharmacological activities for fenfluramine beyond seizure reduction. Plain Language Summary Dravet syndrome is a severe epilepsy disorder that impairs learning and causes premature death. Clinical studies in patients with Dravet syndrome show that fenfluramine reduces convulsive seizures. Additional studies suggest that fenfluramine may have benefits beyond seizures, including promoting survival and improving control over emotions and behavior. Our study is the first to use a Dravet mouse model to investigate nonseizure outcomes of fenfluramine. Results showed that fenfluramine treatment of Dravet mice reduced neuroinflammation significantly more than saline treatment. Fenfluramine‐treated Dravet mice also lived longer than saline‐treated mice. These results support clinical observations that fenfluramine may have benefits beyond seizures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenfluramineEpilepsies, MyoclonicHumansAnimalsMiceAnticonvulsantsZebrafishNeuroinflammatory DiseasesSeizuresDisease Models, AnimalMammalsNAV1.1 Voltage-Gated Sodium Channel

Stichwörter der Autor:innen

Dravet syndromefenfluraminemyelinneuroinflammationsurvival

Substanzen

FenfluramineAnticonvulsantsScn1a protein, mouseNAV1.1 Voltage-Gated Sodium Channel

Autor:innen und Institutionen

  • University of California San Francisco, San Francisco, California, USA.
  • Zogenix, Inc. (now a part of UCB), Emeryville, California, USA.
  • Crosshair Therapeutics, Inc., Sunnyvale, California, USA.
  • WuXi AppTec, Inc., San Francisco, California, USA.
  • UCB Pharma S.A., Colombes, France.

ORCID-Profile: Arnold R Gammaitoni, Amélie Lothe

Förderung

  • Zogenix, Inc., now a part of UCB
  • UCB
  • Zogenix
  • University of California Berkeley

Zitieren

APA

Cha, J., Filatov, G., Smith, S. J., Gammaitoni, A. R., Lothe, A., & Reeder, T. (2024). Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome. Epilepsia Open. https://doi.org/10.1002/epi4.12873

Vancouver

Cha J, Filatov G, Smith SJ, Gammaitoni AR, Lothe A, Reeder T. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome. Epilepsia Open. 2024. doi:10.1002/epi4.12873

BibTeX
@article{Cha2024,
  author = {Cha, John and Filatov, Gregory and Smith, Steven J and Gammaitoni, Arnold R and Lothe, Amélie and Reeder, Thadd},
  title = {Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.12873}
}
Kostenlos starten →